Aisling Capital
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by
Business Model:
Revenue: $15.1M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Aisling Capital Information
Geographic Data
Address: 888 7th Ave
City: New York
State: NY
Zip: 10106
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$423M
Social
Twitter
Linkedin
Crunchbase
Metrics
2,323,328Website Global Rank
8,065Website Monthly Traffic
Twitter Followers
Description
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
Contact Phone:
+12126516380
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2014 | Miramar Labs | Series D | 26M |
| 3/2012 | Cytos | Post-IPO Equity | 40M |
| 4/2007 | Bioenvision | Venture Round | 7.4M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 4/2004 | Cardiokine | Series A | 37M |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 7/2012 | Agile Therapeutics | Series C | 0 |
| 3/2015 | Aimmune Therapeutics | Series B | 80M |
| 4/2013 | Esperion | Venture Round | 33M |
| 9/2022 | Forge Biologics | Series C | 0 |
| 5/2013 | ViewRay | Venture Round | 15M |
| 1/2016 | Syros Pharmaceuticals | Series C | 40M |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 3/2015 | Cynapsus Therapeutics | Venture Round | 16.6M |
| 10/2019 | Nuvation Bio | Series A | 275M |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 1/2015 | LENSAR, Inc. | Private Equity Round | 16M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 6/2009 | Cempra | Series C | 46M |
| 6/2016 | Aclaris Therapeutics | Post-IPO Equity | 20M |
| 4/2006 | Cempra | Series A | 22M |
| 12/2016 | Prolacta Bioscience | Venture Round | 0 |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 6/2017 | Earlens | Series C | 0 |
| 10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 4/2019 | Ajax Health | Series C | 85M |
| 4/2016 | PowerVision | Series D | 10M |
| 3/2013 | T2 Biosystems | Series E | 40M |
| 5/2002 | Advion Inc. | Series B | 15M |
| 10/2014 | Syros Pharmaceuticals | Series B | 53M |
| 7/2013 | Versartis | Series C | 0 |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 8/2014 | Dermira | Series C | 51M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 1/2008 | ViewRay | Series B | 25M |
| 12/2013 | ViewRay | Venture Round | 0 |
| 3/2012 | ViewRay | Series C | 45M |
| 5/2014 | Loxo Oncology | Series B | 24M |
| 6/2016 | Earlens | Series C | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 1/2013 | Versartis | Series C | 0 |
| 2/2014 | Versartis | Series E | 55M |
| 2/2011 | Pharmaron | Series C | 40M |
| 12/2007 | Topaz Pharmaceuticals Inc | Series A | 20M |
| 6/2022 | Dren Bio | Series B | 0 |
| 4/2012 | PreCision Dermatology | Venture Round | 29.4M |
| 6/2016 | F2G | Series E | 60M |
| 10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
| 6/2019 | Ajax Health | Series C | 15M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 10/2007 | Paratek Pharmaceuticals | Post-IPO Equity | 40M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 8/2010 | ViewRay | Series C | 20M |
| 9/2011 | ViewRay | Debt Financing | 10M |
| 2/2012 | ADMA Biologics | Venture Round | 0 |
| 8/2012 | Intercept Pharmaceuticals | Series C | 30M |
| 4/2014 | Earlens | Series B | 40M |
| 7/2007 | Xanodyne | Series A | 25M |
| 4/2018 | Zosano Pharma | Post-IPO Equity | 50M |
| 4/2007 | Sirion Therapeutics | Series B | 45M |
| 1/2017 | Ajax Health | Series A | 95M |
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 7/2021 | Wugen | Series B | 0 |
| 4/2007 | Natural Dentist | Series B | 13.2M |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 7/2020 | Elevation Oncology | Series A | 32.5M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 6/2007 | BioRelix | Series A | 25.8M |
| 7/2014 | Paratek Pharmaceuticals | Post-IPO Debt | 93M |
| 10/2013 | Versartis | Series D | 0 |
| 1/2002 | Allos Therapeutics | Private Equity Round | - |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 1/2012 | Roka Bioscience | Series D | 47.5M |
| 6/2014 | PowerVision | Series D | 30M |
| 10/2013 | LENSAR, Inc. | Debt | 60M |
| 5/2008 | Esperion | Series A | 22.8M |
| 9/2008 | Bridge Pharmaceuticals | Series B | 53.3M |
| 10/2013 | LENSAR, Inc. | Equity | 27M |
| 3/2012 | LENSAR, Inc. | Venture Round | 24M |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 3/2016 | Spirox | Series C | 45M |
| 4/2015 | Spirox | Series B | 18.5M |
| 10/2013 | Loxo Oncology | Series A | 33M |
| 9/2018 | Atreca | Series C | 125M |
| 7/2007 | Cempra | Series B | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 7/2018 | Ajax Health | Series B | 120M |
| 3/2017 | Promentis Pharmaceuticals | Series C | 26M |
| 2/2015 | Agile Therapeutics | Post-IPO Equity | 0 |
| 11/2012 | Ambit Biosciences | Venture Round | 0 |
| 7/2015 | ViewRay | Post-IPO Equity | 0 |
| 9/2017 | GTx | Post-IPO Equity | 48.5M |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 8/2011 | T2 Biosystems | Series D | 0 |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 6/2016 | Miramar Labs | Venture Round | - |
| 4/2010 | Aragon Pharmaceuticals, Inc. | Series B | 22M |
| 11/2015 | ObsEva | Series B | 60M |
| 10/2013 | Seragon Pharmaceuticals | Series A | 30M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 10/2018 | Earlens | Series D | 0 |
| 2/2012 | CeNeRx BioPharma | Series D | 4.6M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 2/2018 | Avrobio | Series B | 60M |
| 6/2022 | Dren Bio | Series B | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 9/2021 | Garuda Therapeutics | Series A | 0 |
| 7/2021 | Wugen | Series B | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 1/2021 | Biomea Fusion | Series A | 0 |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 11/2020 | Elevation Oncology | Series B | 0 |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
